In the Claims

The following amendments are made with respect to the claims in the International application PCT/GB2005/001014.

This listing of claims will replace all prior versions and listings of claims in this application.

1 (original). A pharmaceutical composition in the form of a unit dosage comprising 1 to 60 mg (+)-*erythro*-mefloquine, substantially free of the opposite enantiomer.

2 (currently amended). [[A]] The composition according to claim 1, wherein the unit dosage is a tablet comprising a carrier and/or excipient.

3 (currently amended). [[A]] The composition according to claim 1 ~~or claim 2~~, wherein the unit dosage comprises up to 40 mg (+)-*erythro*-mefloquine.

4 (currently amended). [[A]] The composition according to claim 3, wherein the unit dosage comprises up to 20 mg (+)-*erythro*-mefloquine.

5 (currently amended). [[A]] The composition according to claim 3, wherein the unit dosage comprises up to 15 mg (+)-*erythro*-mefloquine.

6 (currently amended). [[A]] The composition according to ~~any preceding~~ claim 1, wherein the unit dosage comprises at least 5 mg (+)-*erythro*-mefloquine.

7 (currently amended). ~~Use of (+)-*erythro*-mefloquine for the manufacture of a composition according to any preceding claim, for use in~~ A method for the treatment of an inflammatory condition wherein said method comprises administering, to a subject in need of such treatment, a pharmaceutical composition in the form of a unit dosage comprising 1 to 60 mg (+)-*erythro*-mefloquine, substantially free of the opposite enantiomer.

8 (currently amended). [[Use]] The method according to claim 7, wherein the condition is osteoarthritis.

9 (currently amended). [[Use]] The method according to claim 7, wherein the condition is rheumatoid arthritis.

10 (currently amended). ~~Use according to any of claims 7 to 9~~ The method according to claim 7, wherein the condition is also treated with an anti-TNF antibody.

11 (currently amended). ~~Use according to claims 7 to 10~~ The method according to claim 7, wherein the subject of treatment is also receiving an immunosuppressant.

12 (currently amended). [[Use]] The method according to claim 11, wherein the immunosuppressant is methotrexate.

13 (original). A product comprising (+)-*erythro*-mefloquine and an anti-TNF antibody, as a combined preparation for simultaneous, separate or sequential use in the treatment of an inflammatory condition.

14 (original). A product comprising (+)-*erythro*-mefloquine and an immunosuppressant as a combined preparation for simultaneous, separate or sequential use in the treatment of an inflammatory condition and where immunosuppression is also required.

15 (currently amended). [[A]] The product according to claim 14, wherein the immunosuppressant is methotrexate.